Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas
Status:
Completed
Trial end date:
2019-11-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the effectiveness of perifosine in preventing further
tumor growth using the established optimal dose of the drug. A second goal is to determine if
perifosine can block the molecules in the tumor that drive it to divide and grow.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Columbia University Keryx / AOI Pharmaceuticals, Inc. Keryx Biopharmaceuticals Online Collaborative Oncology Group University of Wisconsin, Madison